Raelipskie Partnership’s Novo Nordisk NVO Stock Holding History

Raelipskie Partnership’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$967K	Buy	20,166 +2,318	+13%	+$99.6K	0.37%	52
2026 Q1	$656K	Buy	17,848 +966	+6%	+$45.8K	0.28%	57
2025 Q4	$859K	Sell	16,882 -638	-4%	-$32.6K	0.36%	51
2025 Q3	$972K	Sell	17,520 -805	-4%	-$47.1K	0.42%	48
2025 Q2	$1.26M	Sell	18,325 -300	-2%	-$20.4K	0.58%	44
2025 Q1	$1.29M	Buy	18,625 +3,007	+19%	+$248K	0.66%	39
2024 Q4	$1.34M	Buy	15,618 +3,000	+24%	+$324K	0.67%	38
2024 Q3	$1.5M	Hold	12,618	–	–	0.73%	32
2024 Q2	$1.8M	Buy	+12,618	New	+$1.67M	0.96%	25

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Raelipskie Partnership's NVO Position: Q2 2026 in Review

Raelipskie Partnership increased its Novo Nordisk (NVO) stake by 13% in Q2 2026, buying an estimated $99.6K and bringing the position to 20,166 shares worth $967K. The position accounts for 0.37% of the portfolio, ranked #52.

Raelipskie Partnership first reported a position in NVO in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.8M in Q2 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Raelipskie Partnership held 20,166 shares of Novo Nordisk worth $967K as of Q2 2026.
Raelipskie Partnership bought 2,318 Novo Nordisk shares in Q2 2026, an estimated $99.6K.
Novo Nordisk made up 0.37% of Raelipskie Partnership's portfolio in Q2 2026, its #52 holding.
Raelipskie Partnership first reported a position in Novo Nordisk in Q2 2024 and has held it in 9 quarters since.
Raelipskie Partnership's Novo Nordisk position peaked at $1.8M in Q2 2024.
1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Raelipskie Partnership's 13F filing for Q2 2026, filed 4 Aug 2026.